ReviewJournal of clinical medicine2021
Proposal of the Definition for COVID-19-Associated Coagulopathy.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Protein C and S activities in COVID-19: A systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2024Pooled it
- Thrombotic and Hemorrhagic Incidences in Patients After Discharge from COVID-19 Infection: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Viscoelastic testing: Transforming hemostasis management in patients in the medical intensive care unit.World journal of critical care medicine · 2026Review
- Could persistent extravascular fibrin deposition link microvascular and interstitial pathology in long COVID?Frontiers in medicine · 2026Article
- Thromboinflammation vs. immunothrombosis: strategies for overcoming anticoagulant resistance in COVID-19 and other hyperinflammatory diseases. Is ROTEM helpful or not?Frontiers in immunology · 2025Review
- Serum proteomics for the identification of biomarkers to flag predilection of COVID19 patients to various organ morbidities.Clinical proteomics · 2024Article
- Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024Review
- Rectum necrosis in a patient with severe COVID19 infection after CAR-T therapy: a case report.Surgical case reports · 2024Article
- COVID-19 Coagulopathy.Life (Basel, Switzerland) · 2024Review
- Practical approach to thrombocytopenia in patients with sepsis: a narrative review.Thrombosis journal · 2024Review
- Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study.Annals of vascular diseases · 2024Article
- Report of the ISTH registry on pregnancy and COVID-19-associated coagulopathy (COV-PREG-COAG).Obstetric medicine · 2024Article
- Characterization of the Benefits and Risks of Therapeutic Anticoagulation in Patients Admitted with Severe COVID-19 (CRITAC).The Canadian journal of hospital pharmacy · 2024Article
- Inflammation, immunity and biomarkers in procoagulant responses of critically ill patients.American journal of translational research · 2024Review
- COVID-19 and the Concept of Thrombo-Inflammation: Review of the Relationship between Immune Response, Endothelium and Coagulation.Journal of clinical medicine · 2023Review
- Thromboinflammation in long COVID-the elusive key to postinfection sequelae?Journal of thrombosis and haemostasis : JTH · 2023Review
- Article
- Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience.Journal of clinical medicine · 2023Article
- Pathways of Coagulopathy and Inflammatory Response in SARS-CoV-2 Infection among Type 2 Diabetic Patients.International journal of molecular sciences · 2023Review
- Thromboprophylaxis in Pregnant Women with COVID-19: An Unsolved Issue.International journal of environmental research and public health · 2023Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
Abstract
Thrombotic events are common complications in COVID-19 patients that include both thrombus formation in large vessels and the microvasculature of the lung and other organs. COVID-19-associated coagulopathy (CAC) and disseminated intravascular coagulation (DIC) have similarities and differences, and whether CAC is a form of DIC is the subject of debate. Reported mechanisms of CAC include activated coagulation, endotheliopathy, up-regulated innate and adaptive immunity, and activated complement system. Although the clinical features and laboratory findings of CAC and DIC seem different, there are fundamental similarities that should be considered. Basically, the pathological findings of COVID-19 fall within the scope of the definition of DIC, i.e., systemic activation of coagulation caused by or resulting from the microvascular damage. Therefore, we suggest that although CAC differs from usual infection-associated DIC, its various features indicate that it can be considered a thrombotic phenotype DIC. This review summarizes the current knowledge about CAC including differences and similarities with sepsis-associated DIC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.